ISSUE: Is HTA derived value based pricing the right basis for Middle and Low Income Country (MLIC) decisions about which drugs to include in universal health coverage (UHC) benefit packages? OVERVIEW: The World Health Organisation (WHO) is arguing that value-based pricing alone is not a viable basis for the correct basis for assessing essential life-saving medicines. In addition to looking at differential pricing, cost-effectiveness and local thresholds, it argues for “fair pricing” that also considers affordability and the actual costs of production and research. Adrian Towse will moderate and briefly set the context. Kalipso Chalkidou of the Center for Global Development will support the case for HTA as an integral part of MLIC moves to UHC. Sarah Garner of the WHO will make the case for “fair pricing” addressing affordability, the need for effective procurement arrangements, and for transparency of R&D and production costs. Michael Borowitz of the Global Fund, which, alongside GAVI is one of the largest global health drug and vaccine buyers, will set out how the Fund looks at value for money and procurement, and give his perspective as to how MLICs should assess value in moving towards UHC.